BKM120 in Cancers With PIK3CA Activating Mutations
Status:
Withdrawn
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
In people whos cancers have a PIK3CA mutation, this trial will be evaluating the drug BKM120
as a possible treatment. BKM120 works by blocking the phosphatidylinositol-3-kinase
(PI3K)pathway, thereby inhibiting tumor growth and survival.
The purpose of this study is to learn if the study drug BKM120 can shrink or slow the growth
of your tumor. The safety of BKM120 will also be studied. Your physical state, symptoms,
change in the size of your tumor, and laboratory findings obtained while you are on study
will help the research team decide if BKM120 is safe and effective in patients with advanced
cancers.